Key Points
- Director Quiros Juan Jose Chacon sold a total of 37,500 shares in two transactions (33,925 on Mar 23 and 3,575 on Mar 25) for about $2.26 million, while still holding 1,220,004 shares valued at roughly $73.3 million.
- Establishment Labs reported ($0.09) EPS that beat estimates and revenue of $64.62M (up 45.2% YoY) but remains unprofitable with negative ROE and net margin, and analysts maintain a consensus "Moderate Buy" with a $86.86 average price target.
Establishment Labs Holdings Inc. (NASDAQ:ESTA - Get Free Report) Director Quiros Juan Jose Chacon sold 3,575 shares of the stock in a transaction that occurred on Wednesday, March 25th. The shares were sold at an average price of $60.08, for a total transaction of $214,786.00. Following the sale, the director directly owned 1,220,004 shares of the company's stock, valued at $73,297,840.32. The trade was a 0.29% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Quiros Juan Jose Chacon also recently made the following trade(s):
- On Monday, March 23rd, Quiros Juan Jose Chacon sold 33,925 shares of Establishment Labs stock. The shares were sold at an average price of $60.39, for a total transaction of $2,048,730.75.
Establishment Labs Stock Performance
Shares of ESTA stock opened at $55.31 on Friday. The company has a current ratio of 3.04, a quick ratio of 2.00 and a debt-to-equity ratio of 10.51. The company has a market cap of $1.62 billion, a PE ratio of -31.79 and a beta of 0.91. Establishment Labs Holdings Inc. has a 12-month low of $26.56 and a 12-month high of $83.31. The business's fifty day simple moving average is $68.98 and its 200-day simple moving average is $62.04.
Establishment Labs (NASDAQ:ESTA - Get Free Report) last announced its earnings results on Tuesday, February 24th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.13. Establishment Labs had a negative return on equity of 201.79% and a negative net margin of 24.19%.The firm had revenue of $64.62 million for the quarter, compared to the consensus estimate of $63.80 million. During the same period in the previous year, the business earned ($1.19) EPS. The firm's revenue for the quarter was up 45.2% on a year-over-year basis. Analysts expect that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Establishment Labs
Hedge funds and other institutional investors have recently bought and sold shares of the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Establishment Labs by 20.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 57,215 shares of the company's stock worth $2,335,000 after purchasing an additional 9,557 shares during the last quarter. Geode Capital Management LLC grew its holdings in Establishment Labs by 1.2% in the second quarter. Geode Capital Management LLC now owns 25,917 shares of the company's stock valued at $1,105,000 after purchasing an additional 299 shares during the period. SG Americas Securities LLC grew its stake in Establishment Labs by 94.2% in the 2nd quarter. SG Americas Securities LLC now owns 8,712 shares of the company's stock valued at $372,000 after acquiring an additional 4,226 shares during the period. JPMorgan Chase & Co. raised its position in shares of Establishment Labs by 0.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 373,112 shares of the company's stock worth $15,936,000 after purchasing an additional 1,719 shares during the last quarter. Finally, Tejara Capital Ltd lifted its position in shares of Establishment Labs by 39.0% in the second quarter. Tejara Capital Ltd now owns 78,108 shares of the company's stock valued at $3,336,000 after acquiring an additional 21,898 shares in the last quarter. Institutional investors and hedge funds own 72.91% of the company's stock.
Analyst Ratings Changes
Several equities analysts have recently issued reports on ESTA shares. BTIG Research upped their price objective on shares of Establishment Labs from $86.00 to $88.00 and gave the company a "buy" rating in a report on Tuesday, February 24th. JPMorgan Chase & Co. lifted their target price on shares of Establishment Labs from $71.00 to $80.00 and gave the stock an "overweight" rating in a research note on Wednesday, December 17th. Canaccord Genuity Group boosted their target price on shares of Establishment Labs from $85.00 to $90.00 and gave the stock a "buy" rating in a research report on Thursday, February 26th. Needham & Company LLC upped their price target on shares of Establishment Labs from $84.00 to $86.00 and gave the company a "buy" rating in a research note on Tuesday, February 24th. Finally, Wall Street Zen cut shares of Establishment Labs from a "buy" rating to a "hold" rating in a report on Saturday. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $86.86.
Get Our Latest Stock Analysis on ESTA
About Establishment Labs
(
Get Free Report)
Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company's proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.
The company's flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
